233 related articles for article (PubMed ID: 33249369)
21. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
[TBL] [Abstract][Full Text] [Related]
22. Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.
Schreuer M; Meersseman G; van Den Herrewegen S; Jansen Y; Seremet T; Bott A; Chevolet I; Wilgenhof S; Maertens G; Neyns B
Melanoma Res; 2016 Apr; 26(2):157-63. PubMed ID: 26636909
[TBL] [Abstract][Full Text] [Related]
23. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
[No Abstract] [Full Text] [Related]
24. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
27. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
[TBL] [Abstract][Full Text] [Related]
28. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
29. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
Cheng LY; Haydu LE; Song P; Nie J; Tetzlaff MT; Kwong LN; Gershenwald JE; Davies MA; Zhang DY
Sci Rep; 2021 Apr; 11(1):9043. PubMed ID: 33907234
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE; Mäkelä S; Kytölä S; Andersson E; Vihinen P; Ramadan S; Skyttä T; Tiainen L; Vuoristo MS; Tyynelä-Korhonen K; Koivunen J; Kohtamäki L; Aittomäki K; Hernberg M
Acta Oncol; 2022 Oct; 61(10):1263-1267. PubMed ID: 36307938
[TBL] [Abstract][Full Text] [Related]
31. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
32. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
33. Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.
Marsavela G; Reid A; Gray ES; Calapre L
Methods Mol Biol; 2021; 2265():247-263. PubMed ID: 33704720
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG; Brosda S; Ng J; Lonie JM; Belle CJ; Patel K; Koufariotis LT; Wood S; Atkinson V; Smithers BM; Pearson JV; Waddell N; Barbour AP; Bonazzi VF
J Mol Diagn; 2023 Oct; 25(10):771-781. PubMed ID: 37544359
[TBL] [Abstract][Full Text] [Related]
36. Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.
Gray ES; Witkowski T; Pereira M; Calapre L; Herron K; Irwin D; Chapman B; Khattak MA; Raleigh J; Hatzimihalis A; Cebon J; Sandhu S; McArthur GA; Millward M; Ziman M; Dobrovic A; Wong SQ
J Mol Diagn; 2019 May; 21(3):418-426. PubMed ID: 30731208
[TBL] [Abstract][Full Text] [Related]
37. Use of circulating tumoral DNA to guide treatment for metastatic melanoma.
Herbreteau G; Charpentier S; Vallée A; Denis MG
Pharmacogenomics; 2019 Dec; 20(18):1259-1270. PubMed ID: 31596166
[TBL] [Abstract][Full Text] [Related]
38. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
[TBL] [Abstract][Full Text] [Related]
39. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
[TBL] [Abstract][Full Text] [Related]
40. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
